Tag: PRELUDE
Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018
Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...
Serranator Alto serration balloon effective at 30 days in treating critical...
Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have...
Cagent Vascular completes enrolment of PRELUDE study using Serranator Alto device
Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to...
